Covidien’s Mallinckrodt To Buy CNS Therapeutics For $100M
This article was originally published in The Pink Sheet Daily
Executive Summary
Covidien’s pharmaceutical arm Mallinckrodt has announced its plans to acquire St. Paul, MN-based CNS Therapeutics for $100 million. The acquisition will complement Mallinckrodt’s own generic pain therapeutic offerings. Mallinckrodt is on track to be spun out of Covidien in mid-2013.
You may also be interested in...
Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh
CEO-designate and CFO for the Mallinckrodt specialty pharma spin-out from Covidien discuss the strategy for differentiating its products in a competitive analgesic space. Despite a goal of becoming a leading specialty pharma, the new company does not plan to divest its imaging or active pharmaceutical ingredient businesses.
Deals Of The Week: Roche/Galaxy, Mallinckrodt/CNS Therapies, Valeant/QLT
Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.
Spun Out, Covidien Rolls On
Covidien, nearly a year removed from spinning out of scandal-plagued parent Tyco International, is pushing forward as an independent company. Covidien execs are investing in new product creation, sales and marketing efforts, and acquisitions. That means Covidien is about to make a big splash in the device industry, with devices bringing in two-thirds of this ambitious company's revenues.